Navigating 7 Analyst Ratings For Chemours
Chemours Is Maintained at Equal-Weight by Barclays
Barclays Maintains The Chemours(CC.US) With Hold Rating, Cuts Target Price to $21
Goldman Sachs Maintains The Chemours(CC.US) With Hold Rating, Cuts Target Price to $23
Morgan Stanley Maintains The Chemours(CC.US) With Hold Rating, Maintains Target Price $30
Chemours Analyst Ratings
BMO Capital Maintains The Chemours(CC.US) With Buy Rating, Cuts Target Price to $30
Barclays Maintains The Chemours(CC.US) With Hold Rating, Cuts Target Price to $22
Chemours Analyst Ratings
UBS Upgrades Chemours to Buy From Neutral, Raises Price Target to $30 From $28
Chemours Analyst Ratings
Barclays Keeps Their Hold Rating on Chemours Company (CC)
Chemours Upgraded at BMO Capital After Internal Audit Completed
Chemours Analyst Ratings
Chemours Analyst Ratings
Research Alert: CFRA
Chemours Analyst Ratings
Chemours Analyst Ratings
Chemours Company (CC) Receives a Buy From RBC Capital
Chemours Analyst Ratings